Your session is about to expire
← Back to Search
Binimetinib + Hydroxychloroquine for Pancreatic Cancer
Study Summary
This trial is testing a combination of two drugs to treat patients with pancreatic cancer that has spread to other parts of the body. The first drug, binimetinib, works by blocking some of the enzymes needed for cell growth. The second drug, hydroxychloroquine, may prevent a process called autophagy, where cells destroy proteins and other substances. Autophagy may protect tumor cells by destroying anticancer drugs or substances taken up by them. Giving hydroxychloroquine together with binimetinib may work better in treating patients with pancreatic cancer compared to binimetinib alone.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have been using steroids for a long time to manage pain or nausea.You have certain liver diseases, active tuberculosis, or can't handle imaging tests.Taking certain medications.You need to have certain levels of blood cells and chemicals in your blood.You have at least one visible and measurable abnormality according to specific guidelines.You have received treatment for cancer that has spread to other parts of your body.Tests show that your tumor has a specific mutation called KRAS.You are able to carry out all your normal activities without any restrictions, or you are limited in physically strenuous activity but can still do light work.You have a history of cancer spreading to the brain or spinal cord.You have a history of or are at risk for a certain eye condition called retinal vein occlusion.You currently have a serious infection that needs treatment throughout your body.You have an eye condition that could affect your vision.You have a history of blood clots or stroke.You have had significant bleeding that needed a blood transfusion in the 3 months before screening.You have a history of liver or gallbladder problems caused by drugs.Your ability to perform daily activities has gotten worse in the month before joining the study.You have had a solid organ or blood-related transplant.You have a muscle or nerve condition that causes high levels of creatine kinase.You have mental health or substance abuse issues that could make it hard for you to take part in the trial.Women who could become pregnant must have a negative pregnancy test.You have a blockage in your intestines.You have a stomach or intestine problem that could make it hard for the drug to work in your body.You have had psoriatic arthritis or porphyria, or you cannot safely have a tumor biopsy.You have been diagnosed with pancreatic cancer that has spread to other parts of the body according to specific medical criteria.You have a type of pancreatic tumor that is not adenocarcinoma.You have recently had cancer treatment or a major surgery.You have a heart condition that affects your health.You have a condition that affects how your body absorbs medication in your stomach and intestines.Any health issues or treatments that could make it hard to understand the trial results.You have taken a medication called a MEK or ERK inhibitor before.
- Group 1: Treatment (binimetinib, hydroxychloroquine)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there still opportunities available to participants in this research trial?
"According to clinicaltrials.gov, this research is actively seeking participants. Initially posted on October 22nd 2019 and most recently updated on July 13th 2022, the trial is open for enrollment now."
What is the maximum capacity of participants for this trial?
"Affirmative. The details on clinicaltrials.gov suggest that this trial is currently enrolling participants, having been first posted in October of 2019 and last updated in July 2022. 39 individuals are being recruited from a single research centre for the study."
Has Binimetinib been granted authorization by the FDA?
"Due to the preliminary nature of Binimetinib's clinical data, our team assessed it with a score of 1. This is in keeping with Phase 1 trials which provide limited evidence regarding safety and efficacy."
What other investigations have been conducted regarding Binimetinib's efficacy?
"Presently, there are 121 trials exploring the potential of Binimetinib with 10 being in Phase 3. Although Cambridge is home to the majority of these experiments, 3857 different centres globally have active clinical trials relating to this drug."
Share this study with friends
Copy Link
Messenger